Inhaled adenosine A(2A) receptor agonists for the treatment of chronic obstructive pulmonary disease

Bioorg Med Chem Lett. 2008 Feb 15;18(4):1284-7. doi: 10.1016/j.bmcl.2008.01.033.

Simon J Mantell ¹, Peter T Stephenson, Sandra M Monaghan, Graham N Maw, Michael A Trevethick, Michael Yeadon, Ruth F Keir, Don K Walker, Rhys M Jones, Matthew D Selby, David V Batchelor, Stuart Rozze, Helene Chavaroche, Tim J Hobson, Peter G Dodd, Arnaud Lemaitre, Karen N Wright, Emilio F Stuart

Affiliations

Affiliation

1 Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Kent CT13 9NJ, United Kingdom.

PMID: 18243699 DOI: 10.1016/j.bmcl.2008.01.033

Abstract

COPD is a major cause of mortality in the western world. A(2A) agonists are postulated to reduce the lung inflammation that causes COPD. The cardiovascular effects of A(2A) agonists dictate that a compound needs to be delivered by inhalation to be therapeutically useful. A strategy of minimizing side-effect liability by maximizing systemic clearance was followed and pharmacological and pharmacokinetic SAR of a series of inhaled A(2A) agonists described. A sevenfold improvement in potency and 150-fold reduction in side-effect liability over the lead compound CGS-21680, were obtained.

Name
Email *

	Sorry, but the email address you supplied was invalid.